文献速递乳腺癌放疗放疗物理与技术

免疫细胞有效剂量对乳腺癌患者生存的影响

The impact of effective dose to the immune cells on survival in breast cancer patients.
PubMed 文献 · Clin Transl Radiat Oncol · 2026-08-12

该回顾性队列纳入2005年1月至2015年6月接受辅助放疗的I–III期浸润性乳腺癌患者3423例,计算免疫细胞有效剂量(EDIC),中位EDIC为2.1 Gy。多变量分析显示EDIC与乳腺癌死亡独立相关(HR 1.66;95%CI 1.44–1.91),EDIC较高尤其>3.0 Gy与更差乳腺癌特异性生存(BCSS)相关。

要点

  • 辅助放疗乳腺癌患者中,较高EDIC与更差BCSS相关。
  • EDIC>3.0 Gy时关联最明显,多变量HR 1.66(95%CI 1.44–1.91)。
  • 假说认为该效应可能由放射性淋巴细胞减少介导,尚需前瞻验证。

核心结论

  • 接受辅助放疗的乳腺癌患者中,较高EDIC与更差BCSS相关,EDIC>3.0 Gy时关联最明显。

研究设计与样本

  • 回顾性队列研究纳入2005年1月至2015年6月接受辅助放疗的I–III期浸润性乳腺癌患者3423例,中位年龄59岁(IQR 50–67),中位随访7.7年(IQR 5.5–10.8)。

主要发现

  • 710例(20.7%)死亡,其中323例(9.4%)死于乳腺癌。
  • 中位EDIC为2.1 Gy(IQR 1.6–2.7)。
  • 较高EDIC尤其>3.0 Gy与更差BCSS相关。
  • 多变量分析中EDIC与乳腺癌死亡独立相关(HR 1.66;95%CI 1.44–1.91)。

关键数值与推荐

  • EDIC按平均心脏剂量、平均肺剂量及大、小血管的等效均匀剂量计算。
  • EDIC>3.0 Gy与更差BCSS的关联最明显。

临床怎么用

  • 辅助放疗计划评估时可关注EDIC,尤其避免EDIC>3.0 Gy,但其改善肿瘤结局的作用需前瞻性验证。

局限性

  • 为回顾性队列研究,EDIC与BCSS的关联不能证明因果。
  • 放射性淋巴细胞减少介导效应的假说及降低EDIC能否改善肿瘤结局均需前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In patients with thoracic cancers such as lung and esophageal cancer, higher radiation exposure to immune cells is associated with worse survival outcomes. This study aims to determine whether a similar association between Effective Dose to the Immune Cells (EDIC) and BC-specific survival (BCSS) also exists in BC patients. METHODS: This retrospective cohort study included stage I to III invasive BC patients treated with adjuvant radiation therapy (RT) between January 2005 and June 2015. The EDIC was calculated as the equivalent uniform dose of the mean heart dose, mean lung dose and large and small blood vessels. The association between EDIC and BCSS was assessed using univariable and multivariable Cox proportional hazard regression models. RESULTS: The study included 3423 BC patients (median age of 59 years, IQR 50-67) with a median follow-up of 7.7 years (IQR, 5.5-10.8). Overall, 710 patients (20.7%) died, including 323 (9.4%) from BC. The median EDIC was 2.1 Gy (IQR, 1.6-2.7). Higher EDIC, particularly >3.0 Gy, was associated with worse BCSS. In multivariable analysis, EDIC was independently associated with BC mortality (HR 1.66; 95%CI 1.44-1.91), consistent with worse BCSS. CONCLUSIONS: An association between higher EDIC and worse BCSS was observed in patients treated with adjuvant RT, with the association being most pronounced at EDIC levels >3.0 Gy. We hypothesize that this effect may be mediated by radiation-induced lymphopenia; however, whether strategies aimed at reducing EDIC translate into improved oncological outcomes requires prospective validation.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. de Boer SA, Spoor DS, Maduro JH, et al. The impact of effective dose to the immune cells on survival in breast cancer patients. Clin Transl Radiat Oncol. 2026. PMID: 42662902. doi:10.1016/j.ctro.2026.101251

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。